Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. - Wikidata - awgldk - TriplyDB

Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation.

Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation.

http://www.wikidata.org/entity/Q40646262

about

Cellular and molecular mechanisms of fibrosis Macrophages During the Fibrotic Process: M2 as Friend and Foe Molecular mechanisms of renal blood flow autoregulation Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target Matrix metalloproteinases in kidney homeostasis and diseases Activation of the TGFβ pathway impairs endothelial to haematopoietic transition.Epithelial-mesenchymal transition: An emerging target in tissue fibrosis RBP2 induces epithelial-mesenchymal transition in non-small cell lung cancer Phthalimide neovascular factor 1 (PNF1) modulates MT1-MMP activity in human microvascular endothelial cells.Novel pathway compendium analysis elucidates mechanism of pro-angiogenic synthetic small molecule Matrix metalloproteinase 2-integrin alpha(v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study.Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis Macrophage matrix metalloproteinase-9 mediates epithelial-mesenchymal transition in vitro in murine renal tubular cells.Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer.Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy Ochratoxin A-induced renal cortex fibrosis and epithelial-to-mesenchymal transition: molecular mechanisms of ochratoxin A-injury and potential effects of red wine.Vitamin a deficiency and alterations in the extracellular matrix.Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease.Temporal characterization of the development of renal injury in FHH rats and FHH.1BN congenic strains.Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.A glimpse of matrix metalloproteinases in diabetic nephropathy.Progression of kidney disease in non-diabetic patients with coronary artery disease: predictive role of circulating matrix metalloproteinase-2, -3, and -9 Protein-bound uremic toxins induce tissue remodeling by targeting the EGF receptor Transition of mesothelial cell to fibroblast in peritoneal dialysis: EMT, stem cell or bystander?Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD).Deficient degradation of homotrimeric type I collagen, α1(I)3 glomerulopathy in oim mice.Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases.Matrix metalloproteinases as breast cancer drivers and therapeutic targets.Renal interstitial fibrosis: mechanisms and evaluation.New insights into epithelial-mesenchymal transition in kidney fibrosis.Role of serotonin in the regulation of renal proximal tubular epithelial cells.Matrix metalloproteinases in renal development.Prostacyclin signaling in the kidney: implications for health and disease.Enhanced expression of two discrete isoforms of matrix metalloproteinase-2 in experimental and human diabetic nephropathy.Matrix metalloproteinase-2 dysregulation in type 1 diabetes.Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients Protein biomarkers associated with acute renal failure and chronic kidney disease.Reversal of renal disease: is it enough to inhibit the action of angiotensin II?The role of tubular epithelial-mesenchymal transition in progressive kidney disease.Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation

P2860

Q24648892-60FD1200-574E-448B-95D4-E9FB7FDD9BFC Q26774649-901F2DA0-2AD0-4307-AA2B-086A4D7FF73D Q26825286-973B6583-1C45-490D-824B-D61928F43194 Q26864722-1B35E352-B1A8-43CC-9DEC-5344E20FB056 Q27004621-9A67952B-F0BD-4337-88EA-C82488D28FA5 Q27346829-76770159-99A3-4F9F-88E8-2744A5C0CBA5 Q28083351-9C6D1753-24D6-470F-B886-ED61FE7872DB Q28537878-1C378279-BDCC-43CA-AD94-E05EE27CD3E6 Q30435633-ABE91127-526A-4D86-A079-E1F42F445B4C Q30438177-CC8416B7-BB96-434E-ADD2-8823723D9ADB Q30484821-DC6BE547-9FBD-4661-85CA-7E5AFFCAB364 Q33556248-A24ECFD8-E7A8-4889-93C1-872C248755FA Q33703700-7D1CB911-0C36-48FF-A3AB-D93769F323B6 Q33915005-E1A716C4-DC4A-4DBD-9730-E271E554793F Q34067504-2A00AE0B-E18E-4239-A6DB-75DE9474106D Q34572311-BAA7D70F-73C8-4292-9476-EE922AE5CEC8 Q34578064-86CA3C20-3CFE-4EEE-A66B-EB774D826E53 Q34598006-5B00EF9F-0873-4480-92A5-3F5C5B12B6A7 Q34599851-623E31A8-8B71-44AF-925D-BEECDD87D306 Q34784085-06E7C42E-73E6-4D96-B86C-AF44C3452C76 Q34796034-63CF2E37-4FA1-4E25-8EEA-54BF4750D969 Q34906086-064CF23E-624D-4E7F-83A5-F0994B0552DA Q35027277-99F98931-9DB9-473A-91F6-EEC0B13E9CCF Q35106053-B5B82691-6733-401D-B19F-7BD1931EE9A9 Q35194509-C426848F-8123-43C6-A56E-1F538AC4608B Q35489554-C00737E9-17D3-4E13-AEE4-CF2FE8836156 Q35762816-6F88458F-499B-4D66-9F8D-63A3C6FA4EAD Q35892721-749886BC-B9C6-4548-9EDA-4C69AB885542 Q35967489-3D677DDB-1657-4925-A328-F894366341A2 Q36010095-31DE8402-0F81-4088-9D1F-2EF382C6D689 Q36045468-9F45E307-3C64-486F-B5F8-718B15F99916 Q36069463-9ABFA2EC-2F62-4C53-8FAF-5054D8A98E07 Q36188441-53F984A6-D366-4106-BFC4-F340B5BBDC75 Q36274282-1330DE2E-49F3-49F4-8EF3-64C9CB589E89 Q36454493-BE59CC5A-05FD-461B-92B8-E5A45306BE04 Q36610882-0DD3C2A6-3A8F-4260-9CFC-6B08F5504729 Q36619683-753918BC-B577-4765-A8B6-C706E4189913 Q36775273-C707888A-5761-4E50-93CD-13229FB187A2 Q36857879-61FA6246-2569-41B6-818C-5EEE6D7475FF Q36973713-060F67D2-D5B5-4A8B-B104-04C62760FBF3

P2860

Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation.

http://www.wikidata.org/entity/Q40646262

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Gelatinase A (MMP-2) is necess ...... al-mesenchymal transformation.

@en

type

label

Gelatinase A (MMP-2) is necess ...... al-mesenchymal transformation.

@en

prefLabel

Gelatinase A (MMP-2) is necess ...... al-mesenchymal transformation.

@en

P1433

Q40646262-39681AEE-E7C2-4EE3-9F78-E4D220656CDE

P1476

Q40646262-F6C98414-D04F-43AB-AD09-9A0F8E5F23B2

P2093

Q40646262-7AA982FE-2388-4FAD-B20C-4F83C5F37360

Q40646262-D9BEB2F9-5B15-43F1-A98D-2D7764E64C43

P2860

Q40646262-01283150-9594-4969-ADE3-0564284364AA

Q40646262-0417ABFD-8492-4223-99E8-A46EF1494FD8

Q40646262-095A6EDB-EF57-4357-9A63-6A9B5C5DE2E5

Q40646262-0C9AE4E8-4930-4B51-8945-8621629B124A

Q40646262-0FD1A6A7-2551-4F6B-B6FA-4C442882A4B2

Q40646262-158BBE9A-4CF6-490E-A87D-5533D4E7B852

Q40646262-1666CB0E-F680-4E5D-A079-5069E9FF849E

Q40646262-17E31D12-5349-4FEC-A474-8FD2001116A6

Q40646262-18198004-162A-470E-8A0B-806DB36CDC3E

Q40646262-1A90D141-AC04-4F42-86F4-9F9B4982E0D3

P304

Q40646262-9E8BC010-A084-42C0-9EAB-3585EED565BE

P31

Q40646262-EBEB12FB-CBF5-42CF-9BEA-4D02FAE3F5E5

P356

Q40646262-04A7B550-006E-48DB-86AD-6C6FE3FDF55D

P407

Q40646262-FBB24327-D6D5-4368-BAF5-7D1F0F5E538D

P433

Q40646262-DDB13F64-940B-4FA8-A5A3-7E37A8D521AD

P478

Q40646262-BE7FF346-B200-47E6-89B3-8CFB1599233F

P577

Q40646262-45E8119A-A182-4E0D-9478-10AB474E589D

P698

Q40646262-BF2D6208-EE4B-45AD-9762-9C5C87A177E8

P932

Q40646262-2460ED04-7E7E-46D1-891F-2D6197E68E5A

P356

S0002-9440(10)64327-1

P1433

The American Journal of Pathology

P1476

Gelatinase A (MMP-2) is necess ...... al-mesenchymal transformation.

@en

P2093

David H Lovett

http://www.w3.org/2001/XMLSchema#string

Sunfa Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed

Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells

Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-beta stimulation

Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5

Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties

Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro

Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases

Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity

Tumor targeting with a selective gelatinase inhibitor.

A unique substrate recognition profile for matrix metalloproteinase-2.

P304

1937-1949

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0002-9440(10)64327-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

162

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12759250

http://www.w3.org/2001/XMLSchema#string

P932

1868144

http://www.w3.org/2001/XMLSchema#string